Peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes

Journal of Medicinal Chemistry

Volumn 47, Issue 17, 2004, Pages 4118-4127

  Henke, Brad R ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; ANTILIPEMIC AGENT; BEZAFIBRATE; CARBAZOLE DERIVATIVE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GW 409544; LY 465608; LY 510929; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RAGAGLITAZAR; ROSIGLITAZONE; STATINE DERIVATIVE; TESAGLITAZAR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DIARRHEA; EDEMA; ENERGY BALANCE; ENZYME BLOOD LEVEL; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FAILURE; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MYOPATHY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; RECEPTOR GENE; RHABDOMYOLYSIS; SHORT SURVEY; SIDE EFFECT; TISSUE SPECIFICITY;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 3843079807     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030631e     Document Type: Short Survey

References (63)

1. Boden, G. Obesity, free fatty acids, and insulin resistance. Curr. Opin. Endocrinol. Diabetes 2001, 8, 235-239.
2. Boden, G.; Shulman, G. I. Free fatty acids in obesity and type 2 diabetes: Defining their role in the development of insulin resistance and β-cell dysfunction. Eur. J. Clin. Invest. 2002, 32, 14-23.
3. Arner, P. Insulin resistance in type 2 diabetes: Role of fatty acids. Diabetes / Metab. Res. Rev. 2002, 18, S5-S9.
4. Mangelsdorf, D. J.; Evans, R. M. The RXR heterodimers and orphan receptors. Cell 1995, 83, 841-850.
5. Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347, 645-650.
6. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Plunket, K. D.; Moore, L. B.; Collins, J. L.; Oplinger, J. A.; Kliewer, S. A.; Gampe, R. T., Jr.; McKee, D. D.; Moore, J. T.; Willson, T. M. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 13919-13924.
7. Staels, B.; Auwerx, J. Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones. Curr. Pharm. Des. 1997, 3, 1-14.
8. Aoyama, T.; Peters, J. M.; Iritani, N.; Nakajima, T.; Furihata, K.; Hashimoto, T.; Gonzalez, F. J. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα). J. Biol. Chem. 1998, 273, 5678-5684.
9. Akiyama, T. E.; Nicol, C. J.; Fievet, C.; Staels, B.; Ward, J. M.; Auwerx, J.; Lee, S. S. T.; Gonzalez, F. J.; Peters, J. M. Peroxisome proliferator-activated receptor-α regulates lipid homeostasis, but is not associated with obesity: studies with congenic mouse lines. J. Biol. Chem. 2001, 276, 39088-39093.
10. Guerre-Millo, M.; Rouault, C.; Poulain, P.; Andre, J.; Poitout, V.; Peters, J. M.; Gonzalez, F. J.; Fruchart, J.-C.; Reach, G.; Staels, B. PPAR-α-null mice are protected from high-fat diet-induced insulin resistance. Diabetes 2001, 50, 2809-2814.
11. Spiegelman, B. M. PPARγ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47, 507-514.
12. Kubota, N.; Terauchi, Y.; Miki, H.; Tamemoto, H.; Yamauchi, T.; Komeda, K.; Satoh, S.; Nakano, R.; Ishii, C.; Sugiyama, T.; Eto, K.; Tsubamoto, Y.; Okuno, A.; Murakami, K.; Sekihara, H.; Hasegawa, G.; Naito, M.; Toyoshima, Y.; Tanaka, S.; Shiota, K.; Kitamura, T.; Fujita, T.; Ezaki, O.; Aizawa, S.; Nagai, R.; Tobe, K.; Kimura, S.; Kadowaki, T. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 1999, 4, 597-609.
13. Miles, P. D. G.; Barak, Y.; He, W.; Evans, R. M.; Olefsky, J. M. Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency. J. Clin. Invest. 2000, 105, 287-292.
14. Auwerx, J. PPARγ, the ultimate thrifty gene. Diabetologia 1999, 42, 1033-1049.
15. Walczak, R.; Tontonoz, P. PPARadigms and PPARadoxes: expanding roles for PPARγ in the control of lipid metabolism. J. Lipid Res. 2002, 43, 177-186.
16. Fitzgerald, M. L.; Moore, K. J.; Freeman, M. W. Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home. J. Mol. Med. 2002, 80, 271-281.
17. Bocher, V.; Pineda-Torra, I.; Fruchart, J.-C.; Staels, B. PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann. N. Y. Acad. Sci. 2002, 967, 7-18.
18. Barbier, O.; Torra, I. P.; Duguay, Y.; Blanquart, C.; Fruchart, J. C.; Glineur, C.; Staels, B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler., Thromb., Vasc. Biol. 2002, 22, 717-726.
19. Willson, T. M.; Brown, P. J.; Sternbach, D. D.; Henke, B. R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 2000, 43, 527-550.
20. Sher, T.; Yi, H. F.; McBride, O. W.; Gonzalez, F. J. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 1993, 32, 5598-5604.
21. Brown, P. J.; Winegar, D. A.; Plunket, K. D.; Moore, L. B.; Lewis, M. C.; Wilson, J. G.; Sundseth, S. S.; Koble, C. S.; Wu, Z.; Chapman, J. M.; Lehmann, J. L.; Kliewer, S. A.; Willson, T. M. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPAR2α agonist with potent lipid-lowering activity. J. Med. Chem. 1999, 42, 3785-3788.
22. Kobayashi, M.; Shigeta, Y.; Hirata, Y.; Omori, Y.; Sakamoto, N.; Nambu, S.; Baba, S. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study. Diabetes Care 1988, 11, 495-499.
23. Elisaf, M. Effects of fibrates on serum metabolic paramters. Curr. Med. Res. Opin. 2002, 18, 269-276.
24. Muscari, A.; Puddu, G. M.; Puddu, P. Lipid-lowering drugs: are adverse effects predictable and reversible? Cardiology 2002, 97, 115-121.
25. Mudaliar, S.; Henry, R. R. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu. Rev. Med. 2001, 52, 239-257.
26. Lehmann, J. M.; Moore, L. B.; Simth-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 1995, 270, 12953-12956.
27. Forman, B. M.; Tontonoz, P.; Chen, J.; Brun, R. P.; Spiegelman, B. M.; Evans, R. M. 15-Deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995, 83, 803-812.
28. Mudaliar, S.; Henry, R. R. PPAR agonists in health and disease: a pathophysiologic and clinical overview. Curr. Opin. Endocrinol. Diabetes 2002, 9, 285-302.
29. Vazquez, M.; Merlos, M.; Adzet, T.; Laguna Juan, C. Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition. Br. J. Pharmacol. 1996, 117, 1155-1162.
30. Chaput, E.; Saladin, R.; Silvestre, M.; Edgar, A. D. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem. Biophys. Res. Commun. 2000, 271, 445-450.
31. Murakami, K.; Tobe, K.; Ide, T.; Mochizuki, T.; Ohashi, M.; Akanuma, Y.; Yazaki, Y.; Kadowaki, T. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPARa) and PPARγ: effect of PPARα activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 1998, 47, 1841-1847.
32. Nomura, M.; Kinoshita, S.; Satoh, H.; Maeda, T.; Murakami, K.; Tsunoda, M.; Miyachi, H.; Awano, K. (3-Substituted benzyl)-thiazolidine-2,4-diones as structurally new antihyperglycemic agents. Bioorg. Med. Chem. Lett. 1999, 9, 533-538.
33. Yajima, K.; Hirose, H.; Fujita, H.; Seto, Y.; Fujita, H.; Ukeda, K.; Miyashita, K.; Kawai, T.; Yamamoto, Y.; Ogawa, T.; Yamada, T.; Saruta, T. Combination therapy with PPARγ and PPARα agonists increases glucose-stimulated insulin secretion in db/ db mice. Am. J. Physiol. 2003, 284, E966-E971.
34. Wagner, J. A.; Chun, X.; Rippley, R. K.; Miller, J. L.; Ballaux, D.; De Smet, M.; Gottesdiener, K. M.; Keymeulen, B. Single and Multiple Doses of MK-767 (KRP-297) Reduce Free Fatty Acids (FFA) and Lipids in Healthy Subjects. Diabetes 2003, 52 (Suppl. 1), 588-P.
35. Ljung, B.; Bamberg, K.; Dahllof, B.; Kjellstedt, A.; Oakes Nicholas, D.; Ostling, J.; Svensson, L.; Camejo, G. AZ 242, a novel PPARα/γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J. Lipid Res. 2002, 43, 1855-1863.
36. Cronet, P.; Petersen, J. F.; Folmer, R.; Blomberg, N.; Sjoblom, K.; Karlsson, U.; Lindstedt, E. L.; Bamberg, K. Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 2001, 9, 699-706.
37. Lohray, B. B.; Lohray, V. B.; Bajji, A. C.; Kalchar, S.; Poondra, R. R.; Padakanti, S.; Chakrabarti, R.; Vikramadithyan, R. K.; Misra, P.; Juluri, S.; Mamidi, N. V. S. R.; Rajagopalan, R. (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl] -2-ethoxypropanoic Acid [(-)DRF 2725]: A Dual PPAR Agonist with Potent Antihyperglycemic and Lipid Modulating Activity. J. Med. Chem. 2001, 44, 2675-2678.
38. Sauerberg, P.; Pettersson, I.; Jeppesen, L.; Bury, P. S.; Mogensen, J. P.; Wassermann, K.; Brand, C. L. Sturis, J.; Woldike, H. F.; Fleckner, J.; Andersen, A.-S. T.; Mortensen, S. B.; Svensson, L. A.; Rasmussen, H. B.; Lehmann, S. V.; Polivka, Z. Novel tricyclic-α-alkyloxyphenylpropionic acids: dual PPARα/γ agonists with hypolipidemic and antidiabetic activity. J. Med. Chem. 2002, 45, 789-804.
39. Liu, K. G.; Smith, J. S.; Ayscue, A. H.; Henke, B. R.; Lambert, M. H.; Leesnitzer, L. M.; Plunket, K. D.; Willson, T. M.; Sternbach, D. D. Identification of a series of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids with activity on PPARα, PPARγ, and PPARδ. Bioorg. Med. Chem. Lett. 2001, 11, 2385-2388.
40. Miller, A. R.; Etgen, G. J. Novel peroxisome proliferator-activated receptor ligands for type 2 diabetes and the metabolic syndrome. Expert Opin. Invest. Drugs 2003, 12, 1489-1500.
41. Brooks, D. A.; Etgen, G. J.; Rito, C. J.; Shuker, A. J.; Dominianni, S. J.; Warshawsky, A. M.; Ardecky, R.; Paterniti, J. R.; Tyhonas, J.; Karanewsky, D. S.; Kauffman, R. F.; Broderick, C. L.; Oldham, B. A.; Montrose-Rafizadeh, C.; Winneroski, L. L.; Faul, M. M.; McCarthy, J. R. Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARα/γ agonists. J. Med. Chem. 2001, 44, 2061-2064.
42. Etgen, G. J.; Oldham, B. A.; Johnson, W. T.; Broderick, C. L.; Montrose, C. R.; Brozinick, J. T.; Misener, E. A.; Bean, J. S.; Bensch, W. R.; Brooks, D. A.; Shuker, A. J.; Rito, C. J.; McCarthy, J. R.; Ardecky, R. J.; Tyhonas, J. S.; Dana, S. L.; Bilakovics, J. M.; Paterniti, J. R., Jr.; Ogilvie, K. M.; Liu, S.; Kauffman, R. F. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-α/γ agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes 2002, 51, 1083-1087.
43. Cheng, P. T.; Chandrasena, G.; Chen, S.; Devasthale, P.; Hariharan, N. BMS-298585 is a novel, uniquely balanced dual activator of peroxisome proliferator activated receptors (PPAR) α and γ with an excellent ADME profile. Diabetes 2002, 51 (Suppl. 2), 381-P.
44. Desai, R. C.; Han, W.; Metzger, E. J.; Bergman, J. P.; Gratale, D. F.; MacNaul, K. L.; Berger, J. P.; Doebber, T. W.; Leung, K.; Moller, D. E.; Heck, J. V.; Sahoo, S. P. 5-Aryl thiazolidine-2,4-diones: discovery of PPAR dual α/γ agonists as antidiabetic agents. Bioorg. Med. Chem. Lett. 2003, 13, 2795-2798.
45. Adams, A. D.; Yuen, W.; Hu, Z.; Santini, C.; Jones, A. B.; MacNaul, K. L.; Berger, J. P.; Doebber, T. W.; Moller, D. E. Amphipathic 3-Phenyl-7-propylbenzisoxazoles; human PPAR γ, δ and α agonists. Bioorg. Med. Chem. Lett. 2003, 13, 931-935.
46. Ebdrup, S.; Pettersson, I.; Rasmussen, H. B.; Deussen, H.-J.; Jensen, A. F.; Mortensen, S. B.; Fleckner, J.; Pridal, L.; Nygaard, L.; Sauerberg, P. Synthesis and Biological and Structural Characterization of the Dual-Acting Peroxisome Proliferator-Activated Receptor α/γ Agonist Ragaglitazar. J. Med. Chem. 2003, 1306-1317.
47. Lewis, M. C.; Winegar, D. A.; Bodkin, N. L.; Hansen, B. C.; Oliver, W. R., Jr. Improved insulin sensitivity and dyslipidemia following oral administration of combination PPARγ/α and PPARδ agonists in obese rhesus monkeys. Diabetes 2002, 51 (Suppl. 2), 566-P.
48. Jones, A. B. Peroxisome proliferator-activated receptor (PPAR) modulators: Diabetes and beyond. Med. Res. Rev. 2001, 21, 540-552.
49. Palmer, C. N. A.; Hsu, M.-H.; Griffin, K. J.; Raucy, J. L.; Johnson, E. F. Peroxisome proliferator activated receptor-α expression in human liver. Mol. Pharmacol. 1998, 53, 14-22.
50. Gervois, P.; Torra, I. P.; Chinetti, G.; Grotzinger, T.; Dubois, G.; Fruchart, J.-C.; Fruchart-Najib, J.; Leitersdorf, E.; Staels, B. A truncated human peroxisome proliferator-activated receptor a splice variant with dominant negative activity. Mol. Endocrinol. 1999, 13, 1535-1549.
51. Lambe, K. G.; Woodyatt, N. J.; Macdonald, N.; Chevalier, S.; Roberts, R. A. Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter. Toxicol. Lett. 1999, 110, 119-127.
52. Holden, P. R.; Tugwood, J. D. Peroxisome proliferator-activated receptor α: role in rodent liver cancer and species differences. J. Mol. Endocrinol. 1999, 22, 1-8.
53. Vu-Dac, N.; Chopin-Delannoy, S.; Gervois, P.; Bonnelye, E.; Martin, G.; Fruchart, J.-C.; Laudet, V.; Staels, B. The nuclear receptors peroxisome proliferator-activated receptor α and Rev-erbα mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J. Biol. Chem. 1998, 273, 25713-25720.
54. Foxworthy, P. S.; White, S. L.; Hoover, D. M.; Eacho, P. I. Effect of ciprofibrate, bezafibrate, and LY171883 on peroxisomal β-oxidation in cultured rat, dog, and rhesus monkey hepatocytes. Toxicol. Appl. Pharmacol. 1990, 104, 386-394.
55. Dirven, H. A. A. M.; van den Broek, P. H. H.; Peeters, M. C. E.; Peters, J. G. P.; Mennes, W. C.; Blaauboer, B. J.; Noordhoek, J.; Jongeneelen, F. J. Effects of the peroxisome proliferator mono-(2-ethylhexyl) phthalate in primary hepatocyte cultures derived from rat, guinea pig, rabbit and monkey. Relationship between interspecies differences in biotransformation and peroxisome proliferating potencies. Biochem. Pharmacol. 1993, 45, 2425-2434.
56. Strand, J.; Sandeman, D.; Skovsted, B.; Edsberg, B.; Muller, P. Ragaglitazar: The efficacy and safety of a novel dual PPARα and PPARγ agonist in patients with type 2 diabetes. Diabetes 2002, 51 (Suppl. 2), 583-P.
57. Henke, B. R.; Blanchard, S. G.; Brackeen, M. F.; Brown, K. K.; Cobb, J. E.; Collins, J. L.; Harrington, W. W., Jr.; Hashim, M. A.; Hull-Ryde, E. A.; Kaldor, I.; Kliewer, S. A.; Lake, D. H.; Leesnitzer, L. M.; Lehmann, J. M.; Lenhard, J. M.; Orband-Miller, L. A.; Miller, J. F.; Mook, R. A.; Noble, S. A.; Oliver, W.; Parks, D. J.; Plunket, K. D.; Szewczyk, J. R.; Willson, T. M. N-(2-Benzoylphenyl)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem. 1998, 41, 5020-5036.
58. Sorbera, L. A.; Leeson, P. A.; Martin, L.; Castaner, J. Farglitazar. Antidiabetic PPARγ agonist. Drugs Future 2001, 26, 354-363.
59. Guerre-Millo, M.; Gervois, P.; Raspe, E.; Madsen, L.; Poulain, P.; Derudas, B.; Herbert, J. M.; Winegar, D. A.; Willson, T. M.; Fruchart, J. C.; Berge, R. K.; Staels, B. Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 2000, 275, 16638-16642.
60. Li, A. C.; Brown, K. K.; Silvestre, M. J.; Willson, T. M.; Palinski, W.; Glass, C. K. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 2000, 106, 523-531.
61. Chen, Z.; Ishibashi, S.; Perrey, S.; Osuga, J.-I.; Gotoda, T.; Kitamine, T.; Tamura, Y.; Okazaki, H.; Yahagi, N.; Iizuka, Y.; Shionoiri, F.; Ohashi, K.; Harada, K.; Shimano, H.; Nagai, R.; Yamada, N. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice. Pleiotropic effects on CD36 expression and HDL. Arterioscler., Thromb., Vasc. Biol. 2001, 21, 372-377.
62. Levi, Z.; Shaish, A.; Yacov, N.; Levkovitz, H.; Trestman, S.; Gerber, Y.; Cohen, H.; Dvir, A.; Rhachmani, R.; Ravid, M.; Harats, D. Rosiglitazone (PPARγ agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model. Diabetes, Obes. Metab. 2003, 5, 45-50.
63. Gampe, R. T.; et al. Mol. Cell 2000, 5, 545-555.